

ALCOHOL & DRUG POLICY COUNCIL (ADPC)

Criminal Justice Sub-Committee

Meeting of June 6, 2023

Virtual TEAMS Meeting Minutes

PRESENT: Katie Farrell, Sandra Violette, Barbara Lanza, Haley Russenberger, Rich Doyle, Jenifer Yarsawich, Brian Delude, Karolina Wytrykowska, Daena Murphy, Michael Hines, Michelene Longo, Daniel Varley, Gregory Donah, Stacey Anglade, Brian McManus, Jack Kain, Joseph Murgo, Christopher Cardella, Melissa Sienna, Julia Horan, Kevin Neary, Frankie DeJesus, Gail Hardy, Danielle Ebrahimi, and Kris Robles

Guest Presenters: Francesco Caputo, Neils Cudnohufsky, Lisa Stanz, Ahmad Abedel-Aziz, Sanjay Lalbahadur

Topic	Discussion	Action
Introductions:		
Additions to Agenda/ Review Minutes:	No agenda items added. Minutes approved.	Approved
SUBLOCADE® (buprenorphine extended-release) injection: Frank Caputo	<ul style="list-style-type: none">• Presentation from Indivior team.• Sublocade Drug product overview: extended release buprenorphine that is injected 1x per month. Medication is contained in a gel which turns into a solid depot the size of pencil eraser that is injected into the stomach 1x/month.• This medication works by blocking the euphoric effects of opioid drugs.• Criminal Justice implications-helpful with re-entry to assist with any barriers/gaps in discharge from the facility to linkage to community program. Medication can last for 2-5 months of receptor occupancy and can assist in overdose prevention.• Benefits include steady medication levels, 1x/month vs. daily need to take medications. This long-acting levels above 2 ng/ml meaning they will not experience withdrawal symptoms and cannot feel the euphoric effect (this will continue when discontinued as well, the gradual reduction effect will assist with withdrawal for about 5 months).• Can remain detectable after it has been discontinued for up to 12 months in blood and urine drug screen. It will show decreasing levels but it will be a slow trending down.	

	<ul style="list-style-type: none"> Data: Yale New Haven Health data discussed and Kentucky Treatment Outcome study shows decrease costs, significant reduction in recidivism and improvements in employment, reduction in substance use, etc. 	
Recommendations: ESI MAT at DOC	<p>ESI</p> <ul style="list-style-type: none"> Division of Criminal Justice did not receive funding for ESI expansion, the Chief's States' attorney is moving forward with implementing it with support of outside agencies so he is moving forward to statewide services. The appropriations request was for resource coordinators, this was the cost needed for expansion. <p>MAT at DOC</p> <ul style="list-style-type: none"> Facilities prescribing Suboxone: HCC, Carl Robinson, Willard Cybulski, Osborne YCI will start Sublocade Currently dosing clients who know they have court date but there are still some gaps with late docket additions (this may need some training to reduce late court add on dockets if a client is on MOUD) (asking for 2 day continuance vs. 1 day would reduce this gap and assist in reducing) 	
Workgroup Updates: Recovery Coaches and the CJ population Evaluate/Review training requirement for CJ professional	<p>Plan to start putting together mapping of CT Recovery Coach/Peer resources</p> <p>Training reviews completed- presented recommendations for shared resources and periodic reviews of training standards. Group will continue to meet to formalize recommendation for the full ADPC.</p>	
Other:	The July 5 th sub-committee meeting will be canceled.	
Plans for next meeting:		Email Danielle with new ideas, initiatives, and suggestions for CJ sub-committee recommendations and/or agenda items.
Next meeting:	August 2nd at 1 pm via TEAMS	
Next ADPC meeting:	June 20 th 10am - 12 pm	

